10.1210/clinem/dgz224 106 WhiteP
As a public company, we are required to incur additional costs and obligations in order to comply with SEC rules that implement Section 404 of the Sarbanes-Oxley Act
Nat Genet 49(1):4653 Fomin A, Grtner A, Cyganek L, Tiburcy M, Tuleta I, Wellers L, Folsche L, Hobbach AJ, von Frieling-Salewsky M, Unger A, Hucke A, Koser F, Kassner A, Sielemann K, Streckfu-Bmeke K, Hasenfuss G, Goedel A, Laugwitz KL, Moretti A, Gummert JF, Dos Remedios CG, Reinecke H, Knll R, van Heesch S, Hubner N, Zimmermann WH, Milting H, Linke WA (2021) Truncated titin proteins and titin haploinsufficiency are targets for functional recovery in human cardiomyopathy due to TTN mutations
Carlsson J, Kierstan MPJ, Brocklehurst K
discuss any concerns with your prescribing provider before treatment changes
Research subjects should be fully informed about: The nature and purpose of the research Possible risks and adverse effects Tracking procedures Right to withdraw from research Confidentiality protections Contact data for questions or concerns Regulatory Considerations Researchers should be aware of control frameworks governing peptide research in their jurisdiction
